It thus prepares to close 100 agencies in EnglandGiven the weakness of the increase that won't themFor sponsorship this is the lesson of the eventWhat would in lower cost the benefit from RenaultThe whole process lasts 21 days on averageIn the meantime it is completely blockedGives cities change is much more unlikelyWe have therefore chosen to redeem sharesThe two groups once again refrained from any commentPublic intervention may take several formsAttention, sensitive file! Assistance to the monitoring of drug treatment financed by the laboratories back on the front of the stage in France. One year after the controversy that had forced the Government to withdraw its first project, a new text should be presented to the Senate in early April, indicates to the Palace of Luxembourg. "We have reached a broad consensus," said Maurice-Pierre Planel, Director of the Senate for health insurance.
Proposal for an act in preparation to better supervise the actions implemented by pharmaceutical groups to ensure the proper use of medications. It will come to fill a legal vacuum, because this type of programs already exists in France. The French Agency of sanitary safety of health products in already approved seven. They include injectable products especially for multiple sclerosis and osteoporosis, where the patient education is crucial if the treatment to be effective.
Thus, Eli Lilly funds managed by Mondial Assistance, telephone platform where nurses learn to osteoporosis patients to administer themselves the Forsteo drug with a pen. According to the American laboratory, the results of the program, conducted on patient 5,000 French, are excellent: eight out of 10 followed the entire treatment of eighteen months when they were framed against "virtually no" other patients.
But everyone is not of this opinion. Last year, the previous Bill of the Villepin Government had aroused the wrath of the unions of doctors and patients associations. They had denounced a measure favouring them, an ad disguised for the drug. "The Government gives to the old dream of the pharmaceutical industry, long, attempting to enter into direct communication with patients, by removing the filter of the doctor", the UFC-Que choose tempêtait.
The journal "Prescribe", renowned for its independence from laboratories, remains very critical programmes already set up for multiple sclerosis. "Caregivers have used to explain to patients how to practice the injection, considers." It is unclear what today might require the intervention of a firm in the implementation of this treatment.
Serious pathologies
Before the lifting of shields, the Government had to legislate, requested a report on the subject to the General Inspectorate of Social Affairs (Igas) and entrusted the preparation of a new legislative proposal to Senator Nicolas About on the basis of this report.
The President-elect of the Yvelines is currently completing the hearings of the actors involved, in a climate more quelled than last year, it seems. "Proposals for Igas cut most of our applications," explains Christian Saout, President of the collective of associations of sick CISS. The industry had to restrict its requests. "Laboratories agreed to reduce the scope of the adherence programs from what is allowed in other countries of Europe," said Catherine Lassale, responsible for Medical Affairs at the Leem, which defends the interests of drug companies.
The programs will only cover serious and chronic diseases. No question of allowing them to skin disorders or benign hypertension, as is the case sometimes abroad. They shall concern only the drugs with "a particular complexity of use", says the Igas report. The programs must be accepted by doctors and patients, who may at any time, and the laboratories will not be able to enter into direct contact with them they will have to go through service providers. All procedures will be closely monitored by the health authorities.
